Roth Capital Initiates Coverage On 22nd Century Group with Buy Rating, Announces Price Target of $6
Roth Capital initiates coverage on 22nd Century Group (NASDAQ:XXII) with a Buy rating and announces Price Target of $6.
Analysts’ Take Brought To You On Monday’s Cannabis Daily Podcast
The Best Daily Overview Of The Cannabis Space
22nd Century Group: Q4 Earnings Insights
22nd Century Group (NASDAQ:XXII) reported its Q4 earnings results on Tuesday, March 1, 2022 at 06:00 AM.
Here's what investors need to know about the announcement.
Earnings Preview: 22nd Century Group, Inc. Common Stock
22nd Century Group, Inc. Common Stock (AMEX:XXII) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors need to know before the announcement.
22nd Century Group Announces South Korea As First VLN International Market
22nd Century Group, Inc. (NASDAQ:XXII), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and improving health and wellness through modern plant science,
22nd Century Group Welcomes Dr. Robert Califf’s Confirmation As FDA Commissioner
22nd Century Group, Inc. (NASDAQ: XXII) an agricultural biotechnology company focused on tobacco harm reduction, congratulated Dr.
22nd Century Group And KeyGene Achieve Breakthrough In Hemp/Cannabis GMO Research
22nd Century Group, Inc.
78 Biggest Movers From Friday
Gainers
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) surged 26% to close at $2.24. Y-mAbs reported completion of pre-BLA meeting with the FDA for Omburtamab.